Using CSF-tau as a marker of disease severity that is closely linked to cognitive symptoms in CSF-amyloid-β+ subjects of the DELCODE study, we replicated the findings of a higher preservation of episodic memory and global cognition at more progressed levels of Alzheimer’s disease in participants with higher levels of gLFC-connectivity. Here, MAPT is linked to Alzheimer disease.